Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved

被引：6

作者：

Schmidt, M. ^{[1
]}

Untch, M. ^{[2
]}

机构：

[1] Univ Hosp, Dept Obstet & Gynaecol, Mainz, Germany

[2] Univ Gottingen, Dept Obstet & Gynaecol, Multidisciplinary Breast Canc Ctr, Helios Klinikum Berlin Buch,Acad Hosp, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 03期

关键词：

WOMEN;

D O I：

10.1093/annonc/mdt595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This is a definite statement, however, we want to draw attention to the fact that this evidence is based on two clinical trials including also HER2-positive breast cancer patients. This inclusion of HER2-positive patients might alter the predictive value of RS in luminal HER2-negative breast cancer patients and we thus consider it important to discuss this issue publicly.

引用

页码：754 / 754

页数：1

共 50 条

[21] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
Fujiki, Yoshitaka
Yamamoto, Yutaka
Tomiguchi, Mai
Sueta, Aiko
Takeshita, Takashi
Ibusuki, Mutsuko
Iwase, Hirotaka
CANCER SCIENCE, 2018, 109 : 654 - 654
[22] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
Hamilton, Erika P.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
[23] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
G. Hoste
K. Punie
H. Wildiers
B. Beuselinck
I. Lefever
E. Van Nieuwenhuysen
S. N. Han
P. Berteloot
N. Concin
R. Salihi
I. Vergote
P. Neven
Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
[24] Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Hilbers, Florentine S.
Poncet, Coralie
Tryfonidis, Konstantinos
Viale, Giuseppe
Delaloge, Suzette
Pierga, Jean-Yves
Brain, Etienne G. C.
Rubio, Isabel T.
Thompson, Alastair M.
Rutgers, Emiel J. T.
Piccart, Martine J.
van 't Veer, Laura J.
Cardoso, Fatima
NPJ BREAST CANCER, 2024, 10 (01)
[25] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
Loo, Claudette E.
Rigter, Lisanne S.
Pengel, Kenneth E.
Wesseling, Jelle
Rodenhuis, Sjoerd
Peeters, Marie-Jeanne T. F. D. Vrancken
Sikorska, Karolina
Gilhuijs, Kenneth G. A.
BREAST CANCER RESEARCH, 2016, 18
[26] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
Claudette E. Loo
Lisanne S. Rigter
Kenneth E. Pengel
Jelle Wesseling
Sjoerd Rodenhuis
Marie-Jeanne T. F. D. Vrancken Peeters
Karolina Sikorska
Kenneth G. A. Gilhuijs
Breast Cancer Research, 18
[27] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
Miura, Daishu
Iwatani, Tsuguo
Kawabata, Hidetaka
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
Ueno, Takayuki
CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
[29] 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials
Dar, H. A.
Johansson, A.
Nordenskjold, A.
Yau, C.
Benz, C.
Essermann, L.
Rodriguez-Wallberg, K. A.
Nordenskjold, B. A.
Perez-Tenorio, G.
Stal, O.
Fornander, T.
Lindstrom, L.
ANNALS OF ONCOLOGY, 2022, 33 : S153 - S154
[30] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
Gan, Siyuan
Dai, Haixia
Li, Rujia
Liu, Wang
Ye, Ruifang
Ha, Yanping
Di, Xiaoqing
Hu, Wenhua
Zhang, Zhi
Sun, Yanqin
GLAND SURGERY, 2020, 9 (03) : 661 - 675

← 1 2 3 4 5 →